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Abstract Six subtypes of sporadic Creutzfeldt–Jakob
disease with distinctive clinico-pathological features have
been identified largely based on two types of the abnormal
prion protein, PrPSc, and the methionine (M)/valine (V)
polymorphic codon 129 of the prion protein. The existence
of affected subjects showing mixed phenotypic features and
concurrent PrPSc types has been reported but with incon-
sistencies among studies in both results and their
interpretation. The issue currently complicates diagnosis
and classification of cases and also has implications for
disease pathogenesis. To explore the issue in depth, we
carried out a systematic regional study in a large series of
225 cases. PrPSc types 1 and 2 concurrence was detected in
35% of cases and was higher in MM than in MV or VV
subjects. The deposition of either type 1 or 2, when con-
current, was not random and always characterized by the
coexistence of phenotypic features previously described in
the pure subtypes. PrPSc type 1 accumulation and related
pathology predominated in MM and MV cases, while the
type 2 phenotype prevailed in VVs. Neuropathological
examination best identified the mixed types 1 and 2 features
in MMs and most MVs, and also uniquely revealed the co-
occurrence of pathological variants sharing PrPSc type 2. In
contrast, molecular typing best detected the concurrent
PrPSc types in VV subjects and MV cases with kuru plaques.
The present data provide an updated disease classification
and are of importance for future epidemiologic and trans-
mission studies aimed to identify etiology and extent of
strain variation in sporadic Creutzfeldt–Jakob disease.
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Introduction
Transmissible spongiform encephalopathies (TSEs) or
prion diseases are invariably fatal neurodegenerative dis-
orders affecting humans and other mammals such as sheep,
elk, and cattle [36]. These diseases are characterized clin-
ically by a rapidly progressive neurological dysfunction
and neuropathologically by spongiform degeneration,
neuronal loss, gliosis, and sometimes by amyloid plaques,
which combine in varying degrees of severity and regional
distribution.
Biochemically, prion diseases are characterized by the
conversion of a constitutively expressed cellular protein,
the prion protein (PrPC) into an abnormally folded, insol-
uble, partially protease-resistant isoform (PrPSc) [4, 8, 27].
Incubation of a brain homogenate from prion-infected
individuals with proteinase K (PK) under conditions lead-
ing to a complete degradation of PrPC generates an N-
terminal truncated form of PrPSc, commonly referred to as
PrP27-30, an established molecular marker for the disease
[5, 38].
Sporadic Creutzfeldt–Jakob disease (sCJD), the com-
monest form of the human prion diseases, comprises a
broad spectrum of clinico-pathological variants [30]. Prion
strains are believed to be the main cause of TSE pheno-
typic diversity. Prion strains are defined as isolates that
show distinct disease phenotypes upon transmission to
syngenic animals, persisting on serial transmission [6, 15,
34]. In addition, the host genotype variability in the gene
encoding PrPC (PRNP), as determined by polymorphisms
and mutations, is another recognized causal factor for
phenotypic heterogeneity [2, 12]. The hypothesis that
PrPSc itself may encode strain-specific properties has
gained support over the years by the demonstration of
distinct physico-chemical subtypes of PrPSc that include
differences in the level of glycosylation and in the size of
proteinase K-digested PrPSc fragments, possibly reflecting
distinct protein conformations [1, 3, 9, 10, 14, 22, 28, 29,
32, 39, 41, 42]. Although the final proof that conforma-
tional variants of PrPSc represent the biological basis of
prion strains is lacking, the described physicochemical
differences among PrPSc types are increasingly used as
surrogate markers of strain properties in a given host.
Based on differences in gel mobility and N-terminal
sequence of the core fragments (i.e. PrP27-30) generated
by PK digestion, Parchi et al. [28, 29, 32] originally
identified two major human PrPSc types: type 1 with a
relative molecular mass of 21 kDa and the primary
cleavage site at residue 82, and type 2 with relative
molecular mass of 19 kDa and the primary cleavage site
at residue 97. The two PrPSc types, in conjunction with
the codon 129 genotype, significantly explained sCJD
phenotypic variability and provided a molecular basis for
disease classification [7, 28, 30]. Six subtypes of sCJD
with distinctive phenotypic features were identified, each
resulting from a specific codon 129 genotype/PrPSc type
combination with two exceptions. MM1 and MV1 cases
were phenotypically indistinguishable and, therefore,
merged in one subtype (MM/MV 1), whereas, on the
contrary, MM2 subjects were associated with 2 subtypes
with distinctive histopathological features in the cerebral
cortex and in the thalamus and designated accordingly
(MM2-cortical or MM 2C and MM2-thalamic or MM 2T)
[30]. By showing that at least some of these sCJD sub-
types correspond to specific agent strain-host genotype
combinations, preliminary transmission studies seem to
confirm the biological basis of this classification [16, 17,
23, 42].
An important aspect of sCJD phenotypic variability,
which has not yet been investigated thoroughly, concerns
the existence of cases presenting more than one PrPSc type
and mixed histopathological features. This issue still
represents a potential drawback for the widespread appli-
cation of the current disease classification for diagnostic
and epidemiologic purposes. Since the original report of
this phenomenon [30], based on the analyses of a few
samples for each brain, the co-occurrence of PrPSc type 1
and 2 in a percentage varying between 12 and 44% of
sCJD cases analyzed has been confirmed by a number of
subsequent studies [13, 18, 20, 37, 40, 43]. In many of
them, the question of how far the proportion of cases with
concurrent PrPSc types is a function of the sampling pro-
tocol employed was raised. More recently, two studies
using novel antibodies recognizing an epitope between
residues 82 and 96 (i.e. not detecting type 2) found that all
type 2 samples show at least some associated protein
migrating in the 21 kDa molecular weight range and
concluded that PrPSc type 1 coexists in all type 2 sCJD
cases and that the number of cases with concurrent PrPSc
types is likely larger than previously thought [35, 45]. It
was later shown, however, that the ‘‘type 1 selective’’
antibodies fail to discriminate properly between a bona
fide PK-resistant PrPSc core and the partially cleaved
fragments generated during digestion due to the several
PK cleavage sites included in the PrPSc N-terminus,
making difficult the interpretation of the results obtained
[25].
To explore the issue of concurrent PrPSc types in sCJD
in depth, we carried out a systematic regional study in a
large series of cases. To this aim, we applied a refined
western blot assay with increased sensitivity for the
detection of PrPSc types coexistence [25] and correlated the
molecular data with those obtained by clinical and patho-
logical examinations.
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Materials and methods
Case and tissue selection
This study was based on 225 cases with an established
diagnosis of sCJD obtained after clinical, neuropathologi-
cal, and molecular examination. Cases of genetic and
acquired forms of CJD were excluded. The study was
restricted to cases from which large amounts of both frozen
and fixed brain tissue were available. 200 patients were
obtained from a group of *240 consecutive cases referred
for diagnosis (*40 cases lacked sufficient frozen tissue),
whereas the remaining 25 were specifically chosen to
increase the number of cases with mixed phenotypes. More
precisely, the 25 additional cases were selected based on
the demonstration of a mixed synaptic and perivacuolar
pattern of PrP deposition by PrP immunohistochemistry
(see ‘‘Results’’). 61 patients died in the USA between 1990
and 2001, and 164 in Europe (124 in Italy, 34 in Germany,
and 6 in Belgium) between 1993 and 2007.
Brains were removed at autopsy and either one half or
selected coronal sections of tissue, including all major
brain structures and nuclei, were immediately frozen and
stored at -80C. The remaining tissue was fixed in for-
malin and was used for neuropathological examination and
PrP immunohistochemistry. Samples of frozen gray matter
(between 50 and 100 mg) for protein analysis were
obtained from the following regions: frontal (superior and
middle frontal gyri), temporal (superior and middle tem-
poral gyri), parietal (inferior parietal lobule), and occipital
(calcarine cortex and lateral occipital gyrus) cortices, hip-
pocampus (Ammon’s horn), limbic cortices (entorhinal
cortex anterior, insular cortex, and cingulate gyrus), stria-
tum (caudate and putamen nuclei), thalamus (medial and
lateral nuclei), hypothalamus, brainstem (midbrain peri-
aqueductal gray, pontine periaqueductal gray including
locus coeruleus, medullar periventricular gray), cerebellum
(hemisphere and vermis). The parietal cortex and the 3
samples from the brainstem were not available in 30 cases
from Germany. Furthermore, 1 or 2 samples were occa-
sionally lacking in some other cases [altogether 34
samples, mostly from the hypothalamus (n = 15) and
amygdala (n = 11)]. Sampling of frozen tissues was per-
formed by the same investigator (PP) according to a
defined protocol across the whole series of cases. Blocks of
fixed tissue were taken from the opposite half of the brain
and were used for histopathologic examination. Sampling
of fixed tissues was performed by the same investigator
(PP) according to a defined protocol in 160 cases. The
remaining 65 cases were sampled in Munich (Germany)
and Indianapolis (USA). In these Centers, which are both
involved in CJD National surveillance and Brain banking,
CJD brains are sampled extensively according to protocols,
which included all the areas that were of interest for this
study. Sampling of both fixed and frozen tissue was per-
formed twice in a subgroup of 10 codon 129 MM subjects.
Protein analysis
Preparation of samples, Western blotting (WB), and PrPSc
typing were performed according to established methods
[25, 26, 33]. In particular, for the sensitive detection of
PrPSc types 1 and 2 concurrence, we followed the method
of Notari et al. [25]. All samples were homogenized in lysis
buffer plus at pH 6.9, digested with proteinase K (PK)
(Roche Diagnostics, specific activity by certificate of
analysis: 47.9 U/mg) at a final concentration of 10 U/mL
and run in a 6.5 cm long separating gel. In addition,
selected samples from MV2 cases with kuru plaques (MV
2K) and MM or MV subjects showing mixed pathological
features but only PrPSc type 1 after the run in the 6.5 cm
long gel were also run in a 15 cm long gel. To this aim, at
least one sample from each cortical lobe was re-analyzed.
All immunoblots were probed with the monoclonal anti-
body 3F4 with epitope at PrP residues 108-111 at 0.1 lg/
ml concentration (Signet Labs, MA, USA). In addition,
immunoblots were probed with the monoclonal antibody
1E4 with epitope mapped at PrP residues 98–100 at 2 lg/
ml concentration (Sanquin Reagents, Amsterdam, The
Netherlands) in the following cases: (a) all samples from
VV1 cases; (b) 20 neocortical samples from 10 MM1 cases
with pure synaptic PrP deposition, and (c) all samples from
30 MM or MV cases, which showed a mixed pattern of PrP
deposition by immunohistochemistry and either no evi-
dence or a very scanty and focal (1 or 2 areas) type 2
accumulation after immunoblotting with the 3F4 antibody.
Finally, selected blots from MV 2K samples were also
probed with SAF60 against PrP residues 157–161, at
0.4 lg/ml.
We quantitatively calculated the ratio between type 1
and type 2 in the non-glycosylated PrPSc after densito-
metric analyses of immunoblots probed with 3F4 using the
AIDA Image Analyzer software (RayTest). This choice
was in part driven by our experience indicating that
deglycosylation is associated to a loss of definition in the
type 1 (21 kDa) and type 2 (19 kDa) bands which makes
their distinction and relative quantitation less reliable.
Furthermore, given that it has been previously shown [28,
30] that the relative abundance of glycosylated versus non-
glycosylated PrPSc shows only relatively minor differences
among the sCJD subtypes associated to either PrPSc type 1
or PrPSc type 2, we assumed that the analyses of the
unglycosylated form would be representative of the whole
protein. We tested this hypothesis by comparing densito-
metric analyses of non-glycosylated glycoforms versus
deglycosylated preparations from representative regions of
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MM cases with either a dominant type 1 or a dominant type
2. Overall, we found that, compared to the latter, the first
approach is associated to a relatively minor overestimation
of type 2 protein. In particular, the difference was almost
negligible for the group of samples with dominant type 1
(69/31% on non-glycosylated isoforms vs. 72/28% after
deglycosylation, n = 20), and slightly more evident in the
group of samples with dominant type 2 (29/71% on non-
glycosylated isoforms vs. 37/63% after deglycosylation,
n = 30).
To express quantitatively with a single number the rel-
ative amount of type 1 and type 2 in a given case (total type
1 or type 2 ‘‘load’’) we calculated the mean of the relative
amounts of either type 1 or type 2, expressed in % of total
PrPSc signal, in the different brain regions examined.
Molecular genetic analysis
Genomic DNA from all subjects was used to amplify the
coding region of PRNP in the polymerase chain reaction
(PCR). PRNP open reading frame was amplified as previ-
ously described [11]. The PCR product was visualized on a
1% agarose gel to detect potential insertion mutations or
deletions. Potential point mutations were revealed by
dHPLC analyses. Mutations were also ruled out by direct
sequencing of PRNP open reading frame in about 50% of
cases. Finally, the codon 129 genotype was examined by
digestion with the restriction endonuclease Nsp 1.
Neuropathology
Semiquantitative evaluation of spongiosis and gliosis was
carried out in all cases by comparing hematoxylin and
eosin stained sections obtained from the same 21 brain
regions evaluated biochemically. Spongiosis was rated on a
0–4 scale (not detectable, mild, moderate, severe, and
status spongiosis), whereas gliosis was scored on a 0–3
scale (not detectable, mild, moderate, and severe). A lesion
profile for each patient was obtained by averaging the two
scores.
For PrP immunohistochemistry, paraffin sections from
formalin-fixed and formic acid treated blocks of the areas
selected for neuropathologic examination were processed
using the monoclonal antibodies 3F4, according to pub-
lished protocols [30]. PrP deposits were described as
diffuse or synaptic, perivacuolar, coarse or patchy and
plaque-like.
Clinical analysis
Clinical data were available in most cases, and medical
records always included at least one neurological exami-
nation. Duration of symptoms was calculated from the time
of presentation of neurological signs suggesting an organic
cause. Prodromal symptoms were not taken into account.
Clinical signs were classified ‘‘at onset’’ when observed
within the first quarter of the mean duration of symptoms
of the group to which the patient belonged (i.e. 1 month if
the mean duration was 4).
Results
PrPSc detection and typing
In the present study, we tried to maximize the detection
sensitivity of PrPSc type co-occurrence in sCJD-affected
brains. At variance with previous studies, we typed PrPSc
after a detailed topographic analysis of 21 brain regions
and using the method recently described by Notari et al.
[25], which has shown increased sensitivity for the detec-
tion of bona-fide concurrence of PrPSc types 1 and 2.
Furthermore, we probed selected immunoblots with 1E4, a
recently characterized monoclonal antibody with a higher
affinity for type 2 than for type 1 [44]. The latter approach
allowed us an increased protein loading in the gel and a
better identification of PrPSc type 2 when present in rela-
tively low amounts (Fig. 1a) in the protein types mixture.
The results obtained in the largely unselected series of
200 cases after using both 3F4 and 1E4 antibodies are
shown in Table 1. The overall prevalence of PrPSc types 1
and 2 concurrence was 35% (32% when only the results
with 3F4 were considered). The same incidence of mixed
cases was also found in the two largest groups of subjects
from Italy and USA when considered individually.
Although the protein mixture was detected in each codon
129 genotype (Fig. 1b), PrPSc types 1 and 2 co-occurred
more frequently in MM than in MV or VV subjects. A
PrPSc profile comprising two distinct bands also charac-
terized the MV2 subtype with kuru plaques (MV 2K) in
many brain regions, but the relative size of the associated
band (i.e. 20 kDa) distinguished these profiles from bona-
fide types 1 and 2 concurrence (Fig. 1b), as previously
shown [24, 25].
Regional variation and relative ‘‘load’’ of PrPSc Types 1
and 2 concurrence
MM subjects
The regional distribution of co-existing PrPSc types 1 and 2
in MM subjects reproduced features previously observed in
the pure MM1 and MM2-cortical (MM 2C) sCJD subtypes
[30], although quantitatively the relative proportion of type
1 and type 2 accumulation in these cases varied exten-
sively. Most cases had PrPSc type 1 in all areas and PrPSc
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type 2 detectable only focally in the cerebral neocortex or
thalamus (Fig. 2a), whereas only a small group of subjects
showed a predominant PrPSc type 2 ‘‘load’’ (Fig. 2b). The
two groups will be indicated as MM 1?2C and MM 2C?1
throughout the manuscript, MM 2C?1 being defined as a
case in which the mean total amount of type 2 (total type 2
‘‘load’’) expressed in % of total PrPSc signal and calculated
by averaging the results obtained from all brain regions
examined, is higher than that of type 1 (i.e. [51%).
The detailed regional PrPSc typing in the MM 1?2C
group provided the following results. When 3F4 was used,
74% of cases showed type 2 in 7 or fewer of the 21 regions
analyzed, and 42% of them in only 1 or 2 (Fig. 3). In the
latter group, 3F4 detected the PrPSc types mixture only in
the cerebral cortex or thalamus in 37 of the 504 samples
analyzed (Fig. 3). However, when 1E4 was used, the
number of mixed samples in the cerebral cortex or thala-
mus raised about 2.6 times to 98 (data not shown).
Noteworthy, the number of cases showing type 2 in only
one or two areas dropped from 24 to 8. Furthermore, 1E4
detected PrPSc type 2 in 6 out of 7 subjects in which 3F4
failed to demonstrate the type 2 protein despite its presence
was strongly suggested by the results of PrP immunohis-
tochemistry (see below). Finally, in the remaining samples
from subcortical areas, 1E4 confirmed the results obtained
with 3F4 and failed to reveal a significant type 2
accumulation.
In the group of MM 1?2C with type 2 in up to 7 brain
regions (i.e. 74% of cases), the amount of PrPSc type 1 was
higher than that of type 2 in 84% of the mixed samples,
while type 2 had a stronger signal than type 1 in the
remaining 16%. The mean total type 2 ‘‘load’’ in this
group, calculated on immunoblots probed with 3F4, was
3.4% (range 0.6–14%).
The remaining 26% of MM 1?2C cases showed a more
widespread PrPSc type 2 accumulation involving from 10 to
16 different brain regions. In this group, PrPSc type 1 was
predominant over type 2 in 43% of the mixed samples,
while type 2 had a stronger signal than type 1 in the
remaining 57%. The mean total type 2 ‘‘load’’, again cal-
culated on immunoblots probed with 3F4 raised to 30%
(range 18–38%).
The study of the regional protein distribution in MM
1?2C subjects showed that PrPSc type 2 was overall more
frequently seen in the cerebral cortex than in subcortical
areas (Fig. 3). The temporal, parietal, and occipital neo-
cortices were the cortical areas which preferentially
accumulated the type 2 protein (Fig. 3). Among subcortical
areas, the thalamus was by far the most frequent site of
type 2 accumulation, whereas the brainstem and, to a
greater extent, the cerebellum (Fig. 3) were the regions
with the lowest frequency (1 and 0 cases, respectively) of
type 2 detection.
At variance with MM 1?2C cases, in MM 2C?1 sub-
jects type 2 was the only detectable protein species in some
areas (Fig. 2b, Table 2) and its amount was higher than
that of type 1 also in most areas where the two proteins
coexisted (Table 2).
Table 1 PRNP genotype and PrPSc type in a unselected series of 200
sCJD cases
Typea MM MV VV Total
Type 1 67 (52) 2 (6) 2 (5) 71 (35)
Types 1?2 concurrence 56 (43) 7 (23)b 6 (15) 69 (35)
Type 2 6 (5)b 22 (71)b 32 (80) 60 (30)
Total 129 31 40 200
MV 1?2 includes 2 cases with kuru plaques and 5 without, MM2
includes 4 MM 2T, and 2 MM 2C cases, whereas MV2 includes 20
cases with kuru plaques and 2 without
% are expressed in brackets and refer to each single column
a Typing results refer to both 3F4 and 1E4 mAbs
b Phenotypically heterogenous patient groups
Fig. 1 a mAb 1E4 shows a relative higher affinity for PrPSc type 2
than for PrPSc type 1. Western blot profiles of PrPSc from 3 sCJD MM
subjects showing various relative proportions of PrPSc type 1 and type 2.
Each sample has been loaded twice at the same concentration and
probed either with 3F4 (left) and 1E4 (right). Lane 1 sample with
dominant type 1 and only 3–5% of type 2; Lane 2 sample with 60/
40% type1/type2 ratio; Lane 3 sample with pure type 2. b Western
blot profiles of PrPSc (3F4 antibody) from sCJD subjects with
concurrent PrPSc types 1 and 2 carrying different codon 129 PRNP
genotypes (lanes 2–4). PrPSc type 1 from a MM1 case (lane 1), and
PrPSc type 2 from a VV2 case (lane 6) are included as controls. The
PrPSc profile associated with the sCJD MV2 phenotype with kuru
plaques (sCJD MV2K) is shown in lane 5. The upper band of the
PrPSc doublet in lane 5 migrates faster than the type 1 band. Frontal
cortex homogenates were treated with PK and probed with 3F4.
Approximate molecular masses are in kilodaltons
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MV subjects
PrPSc types 1 and 2 concurrence in MV cases was detected
in two phenotypically distinct groups of subjects. The
absence or presence of kuru plaques best distinguished the
two groups. In subjects lacking kuru plaques, the con-
currence of PrPSc types reproduced the features seen in
MM 1?2C subjects. At variance with the MM group,
however, the relative proportion of MV 1?2C and MV
2C?1 was significantly different. Indeed, only one case
had type 1 in all brain regions and the concurrent type 2
in 5, two had 12 and 14 areas with a mixed molecular
phenotype, respectively (but a predominant type 1 load),
while the remaining 3 showed a predominant type 2
accumulation (Table 3).
PrPSc types 1 and 2 concurrence was more difficult to
assess in MV subjects with kuru plaques (i.e. MV 2K
subtype) because of the presence of the 20 kDa band
(Fig. 1), which we detected in virtually all samples from
subcortical structures and in 75% of those taken from the
neocortex (data not shown). Thus, a relatively weak
21 kDa signal cannot be considered proof of bona-fide
PrPSc type 1 concurrence, since it would also be compatible
with a partially cleaved fragment of the 20 kDa PrPSc core
[25]. As a consequence, we considered the 21 kDa band a
bona-fide type 1 only when its intensity was similar or
higher than that of the 20 kDa fragment. Using these
stringent criteria, we detected an undisputable type 1 signal
in a least two cortical samples in only 2 of the 24 MV 2K
cases analyzed (data not shown). Interestingly, at variance
with the other MV 2K cases, the PrPSc profile in these two
cases included the so called 13 kDa CTF (C-terminal
truncated fragment) (data not shown), which at variance
with MV 2K is consistently found in both MM1 and VV1
cases [26].
Fig. 2 Western blot profiles of
PrPSc (3F4 antibody) from
different brain regions of a one
sCJD MM 1?2C subject
showing the type 2 protein only
focally in the cerebral cortex
(arrowheads) and b one sCJD
MM 2C?1 subject showing a
widespread PrPSc type 2
accumulation, a focal deposition
of the type 1 protein
(arrowheads) in the cerebral
cortex, putamen, and thalamus,
and a dominant type 1 in the
cerebellum. Areas shown
include the middle frontal gyrus
(MFG), middle temporal gyrus
(MTG), parietal cortex (PC),
lateral occipital cortex (OCC2),
insular cortex (INS), putamen
nucleus (PUT), medial thalamic
nuclei (TH1), and cerebellum
(CE). Approximate molecular
masses are in kilodaltons
Fig. 3 Prevalence and regional distribution of PrPSc type 2 in a series
of 57 MM 1?2C subjects. PrPSc type 1 was detected in all areas.
Subjects are divided in 3 groups based on the number of areas with a
detectable PrPSc type 2 signal on WB. For each group, the % of type 2
positive samples in each brain region is shown. The mean total type 2
‘‘load’’ for each group, as defined in ‘‘Materials and methods’’, is given
in brackets. FC frontal cortex, TC temporal cortex, PC parietal cortex,
OCC occipital cortex, Limbic CTX limbic cortices, Hipp ? AMG
hippocampus?amygdala, STR striatum, HYP hypothalamus, TH
thalamus, BRST brainstem, CE cerebellum
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VV subjects
Six VV cases with concurrent PrPSc types 1 and 2 were
found. PrPSc type 2 was always dominant and detectable in
almost all samples. By contrast, type 1 was only present
focally in the cerebral cortex, in the striatum or in both. In
two cases, however, PrPSc type 1 was seen in most samples
from cerebral cortex and striatum and in a single case, it
showed an even more widespread accumulation involving
all the cerebral cortical samples, the striatum, amygdala,
hippocampus, hypothalamus and thalamus (Fig. 4a). When
concurring, type 2 was predominant over type 1 in 76% of
samples, while type 1 had a stronger signal than type 2 in
the remaining 24%. The mean total type 1 ‘‘load’’ in VV
2?1 was 9.4% (range 1.5–38%).
Although clearly distinguishable from a type 1 and 2
concurrence, also the PrPSc type 2 profile in VV subjects
was sometimes characterized by a doublet comprising a
*18.5 kDa fragment in addition to the typical 19 kDa
band (Fig. 4b). These two bands concurred in the cere-
bellum in all cases, in the thalamus in 50% of them and in
the midbrain in 18%. Since epitope mapping indicated that
the 18.5 peptide, like the 19 kDa fragment, has an intact C-
terminus (data not shown), the two fragments likely differ
in their N-terminal PK cleavage site (i.e. the 18.5 fragment
is further cleaved beyond residues 97–99).
Molecular-phenotypic correlations: the pathological
phenotype
The pathological phenotype in MM/MV 1?2C and MM/
MV 2?1C subjects displayed varying relative amounts of
features as previously described in the pure MM/MV 1 and
MM/MV 2C subtypes [30, 33]. The lesion profile in MM/
MV 1?2C largely overlapped with that of pure MM/MV 1
cases, with the exception of the cerebellum, which was less
affected relatively to the cerebral cortex (Fig. 5, and data
not shown). Histopathologic hallmarks in these cases were
(a) ‘‘morula-like’’, sometimes referred to as ‘‘grape-like’’,
confluent foci of spongiform degeneration with large vac-
uoles in addition to the classic microvacuolation, and (b) a
mixed synaptic/perivacuolar or coarse pattern of PrP
deposition (Fig. 6a, b). With the exception of one case, in
which, only the type 1 protein could be demonstrated by
immunoblotting even after the 1E4 staining, in this group
we found a 100% correlation between the large vacuoles
and the perivacuolar staining on one hand and the PrPSc
type 2 detection by immunoblotting on the other. The
extension of the perivacuolar or coarse PrP staining, co-
localizing with the confluent vacuoles varied significantly
from case to case and was overall more common in the
cerebral cortex than in subcortical areas (Fig. 7). The
temporal, parietal and occipital cortices were the most
Table 2 Regional relative amounts (in % ± SD) of PrPSc type 2 in MM 2C?1 subjects (N = 5)
Brain region Type 1 only Type 1 [ 2 Type 2 [ 1 Type 2 only
Neocortex (0) 38 ± 11 (14) 70 ± 18 (46) (40)
Limbic areas (0) 41 ± 3 (16) 77 ± 9 (44) (40)
Striatum (0) 42 ± 8 (20) 78 ± 14 (70) (10)
Thalamus (0) 44 (10) 90 ± 7 (70) (20)
Hypothalamus ? Brainstema (21) 44 ± 4 (14) 75 ± 14 (43) (22)
Cerebellum (70) 38 (10) 61 ± 4 (20) (0)
Numbers in brackets express the % of samples showing each of the 4 profiles in the listed brain regions
a Samples from the brainstem were not available in three cases
Table 3 Regional relative amounts (in % ± SD) of PrPSc type 2 in MV 2C?1 cases (N = 3)
Brain region Type 1 only Type 1 [ 2 Type 2 [ 1 Type 2 only
Neocortex (0) 48 (5) 84 ± 12 (47) (48)
Limbic areas (0) 48 (7) 80 ± 15 (73) (20)
Striatum (0) 33 ± 13 (50) 75 ± 14 (50) (0)
Thalamus (0) 46 (17) 83 ± 4 (83) (0)
Hypothalamus ? Brainstem (8) 32 ± 10 (44) 65 ± 12 (25) (0)
Cerebellum (33) 7 (17) (0) (50)
Numbers in brackets express the % of samples showing each of the 4 PrPSc profiles in the listed brain regions
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affected cortical areas (Fig. 7). Among subcortical struc-
tures, the thalamus most often showed the perivacuolar
staining, whereas the brainstem and to a greater extent the
cerebellum (Fig. 7) were the areas with the lowest
frequency.
The pathological phenotype of MM/MV 2C?1 largely
overlapped to that of MM/MV 2C subjects. However, as a
distinctive feature from the pure MM/MV 2C phenotype,
all these cases had a synaptic pattern of PrP staining in the
cerebellum, which well correlated with the presence of
PrPSc type 1 on western blots.
The lesion profile and the pattern of PrP staining in all 6
VV subjects with concurrent PrPSc types (VV2?1) were
very similar to those of typical VV2 sCJD cases. As the
only distinctive feature, the two cases with the most sig-
nificant type 1 accumulation showed a less consistent
laminar pattern of spongiform degeneration in the cerebral
cortex and a milder cerebellar pathology when compared to
VV2 cases with similar disease duration.
Lastly, the two MV 2K?1 cases had no clear distin-
guishing pathological features although they both showed a
relatively mild pathology and the lack of a laminar pattern
of spongiform degeneration in the cerebral cortex. Of
notice, however, we observed a perivacuolar pattern of
PrPSc deposition co-localizing with the presence of larger
vacuoles in 6 out of 25 of the sCJD MV 2K subjects
(Fig. 6c, d) as well as in one MM2-thalamic (MM 2T) case.
The regional distribution of the perivacuolar staining was
not distinguishable from that observed in MM/MV 1?2C
and mainly involved samples from the cerebral cortex (data
not shown).
Molecular-phenotypic correlations: clinical features
MM/MV 1?2C and MM/MV 2C?1 subjects showed a
significant difference in both disease duration and fre-
quency of symptoms at onset according to the relative load
Fig. 4 a Western blot profiles
of PrPSc (3F4 antibody) from
different brain regions of the
sCJD VV 2?1 subject with the
more significant type 1
deposition. Areas shown include
the middle frontal gyrus (MFG),
middle temporal gyrus (MTG),
parietal cortex (PC), lateral
occipital cortex (OCC2), insular
cortex (INS), putamen nucleus
(PUT), medial thalamic nuclei
(TH1), and cerebellum (CE).
Approximate molecular masses
are in kilodaltons. b Western
blot profiles of PrPSc doublets in
sCJD VV2, sCJD MM 1?2 and
sCJD MV 2K. Lanes 1 and 2
show the association of a
*18.5 kDa fragment with the
typical 19 kDa type 2 band in
sCJD VV2 cerebellum (CE,
V = vermis, H = hemisphere).
Approximate molecular masses
are in kilodaltons
Fig. 5 Relative severity of lesions (i.e. spongiform degeneration and
astrogliosis) in the cerebral cortex (mean of scores in neocortical and
limbic cortical areas) and cerebellum: comparison between MM/MV
1 (n = 65), MM/MV 1?2C (n = 63), MM/MV 2C?1 (n = 9), and
MM/MV 2C (n = 4) sCJD groups. The line slope expresses the ratio
between the degree of cortical and cerebellar pathology. Group MM/
MV 1?2C* includes only the cases within the MM/MV 1?2C group
showing type 2 in at least 5 areas (n = 17)
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of the two protein types (Tables 4, 5). Clinical signs in
MM/MV 1?2C with a limited PrPSc type 2 deposition (up
to 5 brain regions involved) did not significantly differ
from those of MM/MV 1, but the disease duration became
significantly longer and cerebellar signs less frequent at
onset with increasing type 2 load. Thus, MM/MV 2C?1
subjects showed both a disease duration and relative fre-
quency of symptoms at onset consistent with those of sCJD
MM/MV 2C. Age at onset and disease duration in VV 2?1
subjects were consistent with those of sCJD VV2, but the
relative frequency of cognitive decline at onset was higher
than in VV2 cases, although the difference was not statis-
tically significant, probably because of the low number of
VV 2?1 cases. Last, clinical features in the 2 MV 2K?1
subjects were within the spectrum of the MV 2K group.
Discussion
Previous studies have addressed the issue of PrPSc types 1
and 2 co-occurrence in sCJD. Most of them raised the
question of the influence of the number of cases and brain
areas analyzed and emphasized the possibility that the co-
occurrence of PrPSc types 1 and 2 is underestimated [13,
18, 20, 30, 37, 40, 43]. On the other hand, the use of a
novel, potentially very sensitive approach, later shown to
have pitfalls related to the detection of unspecific bands
Fig. 6 a A ‘‘grape-like’’ focus
of spongiform degeneration
with large confluent vacuoles
surrounded by typical
spongiform degeneration with
fine, relatively small vacuoles in
sCJD MM 1?2C (hematoxylin
and eosin 9200, frontal cortex);
b focal perivacuolar staining
surrounded by a synaptic pattern
of PrP immunoreactivity
(9200) in the cerebral cortex
of a sCJD MM 1?2C;
c spongiform degeneration with
large vacuoles (hematoxylin and
eosin 9200) and d perivacuolar
PrP deposition (9200) in the
cerebral cortex of a sCJD MV
2K
Fig. 7 Regional distribution of the coarse/perivacuolar pattern of
PrPSc deposition in 40 MM/MV 1?2C cases divided in 3 groups
according to the number of regions showing the perivacuolar pattern
in individual cases. For each group, the % of cases revealing the
perivacuolar pattern in each brain region is shown. FC frontal cortex,
TC temporal cortex, PC parietal cortex, OCC occipital cortex, Limbic
CTX limbic cortices, Hipp ? AMG hippocampus?amygdala, STR
striatum, HYP hypothalamus, TH thalamus, BRST brainstem, CE
cerebellum
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generated by partially digested PrPSc fragments [25], likely
led other investigators to overestimate the incidence of the
concurrent PrPSc types [35, 45]. Thus, the overall results
on the phenomenon of the coexistence of molecular and
clinico-pathological sCJD subtypes are at present incon-
clusive with respect to incidence, effect on disease
phenotype and criteria for disease classification. To con-
tribute to the full understanding of these issues, in the
present study, we combined a systematic analysis of sev-
eral brain regions in a large series of case including all
codon 129 genotypes and the rarest phenotypes with the
use of a refined methodology for the detection of the PrPSc
type concurrence, which provides good sensitivity com-
bined with high specificity [25].
After screening about 4,200 samples from a largely
consecutive series of 200 cases, we estimated that PrPSc
types 1 and 2 coexist in about 35% of sCJD cases, which is
overall consistent with figures from some of the previous
studies [13, 37, 43] in which the number of cases and areas
analyzed were significantly lower. This finding supports
the idea that PrPSc types co-occurrence involves a relevant
but limited group of sCJD subjects and indicates that the
incidence of the phenomenon had not been significantly
underestimated.
As far as the characteristics of the CJD population with
mixed phenotypes are concerned, our data show that the
PrPSc types 1 and 2 co-occur more frequently in the MM
than in the MV and VV genotypes. More specifically, the
large majority of sCJD cases with concurrent PrPSc types
combines features of the MM and MM 2C sCJD subtypes,
in variable proportions. Most commonly, in such cases, the
MM1 phenotype is predominant over the MM 2C pheno-
type, but the opposite situation also rarely occurs. The
latter results significantly differ from those obtained in
most previous studies. Indeed, Head et al. [13] mainly
found a focal type 1 co-occurrence in MM and MV sub-
jects with dominant type 2, Schoch et al. [40] detected the
mixed protein types mostly in MV2 cases showing the type
1 only focally in subcortical areas, and Uro-Coste et al.
[43] mainly detected a random co-occurrence of type 1 in
MV or VV cases with dominant type 2. Given that only our
study was based on a large series of consecutive cases, we
attribute such heterogeneity of previous results to case
selection biases, although methodological differences may
also have contributed [43].
Since subjects with mixed PrPSc types represent a
significant proportion of the sCJD population, show
distinctive phenotypic features, and potentially represent a
Table 4 Demographic characteristics and classification of patients
sCJD groups MM/MV 1 MM/MV 1?2C MM/MV 2C?1 MM/MV 2C MV 2Ka VV 1 VV 2?1 VV 2
No. cases 66 63 9 4 26 5 6 39
Age at onset (years) 70.1 (48–86) 68.6 (42–89) 65.3 (53–72) 67.8 (61–75) 65.4 (48–81) 39.3 (24–49) 69.3 (59–85) 64.5 (45–83)
Duration* (months) 4.0 (1–24) 4.0 (1–26) 18.1 (6–33) 20.0 (12–36) 15.8 (5–48) 15.3 (14–16) 6.5 (3.5–13) 6.3 (3–18)
a Includes 2 cases with MV 2K?1
* p \ 0.001 between MM/MV 1?2C and MM/MV 2C?1 or between MM/MV 1 and MM/MV 2C?1 (Wilcoxon rank sum test)
Table 5 Symptoms at disease onset (in %) in the sCJD subgroups
sCJD Groups MM/MV 1 MM/MV 1?2C MM/MV 2C?1 MM/MV 2C MV 2Ka VV 1 VV 2?1 VV 2
No. of cases 66 63 17b 9 4 26 5 6 39
Cognitive 74 71 76 89 100 54 100 66 25
Gait or limb ataxia§ 51 28 12 0 0 85 0 100 100
Visual central 32 27 35 22 0 4 0 0 0
Aphasia 15 19 18 33 25 4 20 0 0
Myoclonus 8 0 0 0 0 0 0 0 0
Psychiatric 12 11 17 0 0 0 0 0 2
Pyramidal 6 0 0 0 0 0 0 0 0
Sensory 2 3 0 0 0 12 0 0 5
Other diskynesias 3 2 6 0 0 8 0 0 0
Oculomotor 2 3 0 0 0 0 0 0 18
a Includes 2 MV 2K?1 cases
b Includes only the cases in which PrPSc type 2 was detected in at least 5 areas
§ p \ 0.005 between MM/MV1 and MM/MV 1?2C with more than 5 areas with type 2 and p \ 0.002 between MM/MV 1 and MM/MV 2C?1
(Fisher exact test)
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distinct subtype in terms of biological relevance, it is
important that they are properly identified and are added as
new subtypes in the current sCJD classification (Table 6).
Despite the emphasis on molecular features of current
sCJD classification, it has become increasingly clear that
PrPSc typing alone, when limited to a single or even a few
brain samples, fails to provide an accurate classification in
a significant proportion of cases. This is mainly related to
the focal nature of the ‘‘mixed features’’ in many sCJD
cases with PrPSc types 1 and 2 concurrence. Indeed, we
would have misclassified the disease subtype in about
27.5% (using 3F4) of cases with MM or MV genotype, if
we had analyzed PrPSc only in the frontal cortex, the area
more commonly used for typing worldwide. For the same
reason, discrepancies may arise when PrPSc-typing and PrP
immunohistochemistry are performed from individual
samples taken from opposite hemispheres or even adjacent
cortical gyri. However, our study shows that the regional
deposition of either type 1 or type 2 when concurrent is not
random and that a relatively limited number of critical
brain structures must be assessed to reach an accurate
classification. Furthermore, our results further underline the
importance of applying both molecular and neuropatho-
logical assessment for sCJD subtype classification. In this
regard, the lack of detection of PrPSc type 2 in a minority of
MM subjects, despite the presence of a mixed synaptic and
perivacuolar pattern of PrP deposition, indicates that when
type 2 is very focal or limited in amount, histopathologic
examination is more sensitive in identifying such cases
than PrPSc typing, at least when only the 3F4 antibody is
used. Given the very strong correlation in MM subjects
between PrPSc type 2 detection and the large ‘‘grape-like’’
vacuoles and the perivacuolar pattern of PrP deposition on
histopathologic examination, which is in line with results
previously obtained in other studies [18, 37], we propose
that these cases are classified as MM 1?2C or MV 1?2C
even without the final proof of type 2 detection by western
blot. Alternatively, PrPSc typing using the antibody 1E4
was in our hand as sensitive as the histopathologic exam-
ination in the detection of cases with very focal type 2.
In the light of the present results, the most important
regions to be assessed pathologically include the cerebral
cortex from each of the 4 lobes, the striatum, hippocampus,
thalamus and cerebellum. The cerebellum, in particular, is
critical for the recognition of the synaptic pattern of PrP
deposition as marker of PrPSc type 1 concurrence in the
cases with dominant type 2.
Taken together, our data indicate that a protocol
including the neuropathologic assessment of the eight brain
regions mentioned above and PrPSc typing in four critical
regions such as the temporal, parietal and occipital neo-
cortices, and medial thalamus is strongly recommended for
a reliable sCJD group classification addressing the issue
of mixed phenotypes. Indeed, by applying this protocol
Table 6 Nomenclature and classification of sCJD subtypes
Nomenclaturea %b Distinctive histopathologic features
Pure subtypes
MM/MV 1; VV2; MV 2K;
MM/MV 2C; MM 2T; VV1;
65 Previously established [30] (for a summary see Table 8 in [30])
Mixed subtypes
MM/MV 1?2C 26 As in MM/MV 1 but with clusters of large vacuoles associated
to perivacuolar and coarse PrP deposition mainly in cerebral
cortex or thalamus
MM/MV 2C?1 2 As in MM/MV 2C but with synaptic-type PrP staining in the
molecular layer of the cerebellum
VV 2?1 3 Virtually indistinguishable from VV2
MV 2K?1 1 Virtually indistinguishable from MV 2K
MV 2 K?C 3 As in MV 2K but with clusters of large vacuoles associated to
perivacuolar and coarse PrP deposition mainly in cerebral
cortex
MM 2 T?C \1 As in MV 2T but with clusters of large vacuoles associated to
perivacuolar and coarse PrP deposition mainly in cerebral
cortex
a It is largely based on codon 129 PRNP genotype, which can be either methionine (M) or valine (V) and the PrPSc type (1 or 2 according to
Parchi et al. [28, 29]). Since both MM 2 and MV 2 groups are associated to 2 distinct phenotypes, these are further defined with a third parameter
(capital letter) referring to distinctive histopathological features: K kuru type amyloid plaques, C predominant cortical pathology with confluent
vacuoles and perivacuolar PrP staining, T prominent thalamic pathology with atrophy
b Percentage of total consecutive sCJD cases (n = 200) investigated
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instead of examining all 21 brain regions, we would have
reached the same classification of cases in the present
series.
We also wish to underline the importance of identifying
correctly the sCJD cases with mixed features for trans-
mission purposes. Indeed, the question of whether the
concurrence of PrPSc types 1 and 2 in CJD reflects a co-
infection by two prion strains related to specific undis-
covered human genotypes, or determined by epigenetic
factors remains unanswered and will largely rely on
transmission studies in which the careful selection of
samples will be of critical importance. Concerning this
critical question, we find intriguing that the large, confluent
vacuoles and the perivacuolar pattern of PrPSc deposition,
we originally linked to sCJD MM 2C are also found in a
subgroup of MV 2K subjects in addition to MM/MV
1?2C. In addition, we have described here the same
morphological features in one case of fatal insomnia (i.e.
the MM2-thalamic subtype or MM 2T) which adds to two
previously reported cases [19, 30, 31]. Thus, it seems that
large confluent vacuoles and the perivacuolar pattern of
PrPSc deposition may be found in sCJD associated with all
phenotypes linked to MM or MV at codon 129. Although
this observation remains difficult to interpret at present, it
appears relevant for our future understanding of the
molecular basis and the extent of strain variation in sCJD.
In any case, our observation strongly suggests that the
phenomenon of mixed phenotypes in sCJD goes beyond
PrPSc types 1 and 2 coexistence and also involves subtypes
which shares the same PrPSc type. This, in turn, further
underlines the importance of combining histopathological
assessment and biochemical PrPSc typing for sCJD subtype
characterization.
The present data also show that the association of two
PrP27-30 fragments, which does not represent a bona-fide
type 1 and 2 concurrence, may also be a feature of some
sCJD cases. Thus, the PrP27-30 profile in VV2 cases in the
cerebellum, thalamus and midbrain is sometime character-
ized by a doublet comprising a 18.5 kDa in addition to the
typical 19 kDa band, while the western blot profile of
PrP27-30 in the MV 2K cases appears almost invariably
characterized by the association of two PrPSc core frag-
ments including a classic 19 kDa type 2 band and a slower
migrating band of about 20 kDa. Although these profiles
truly represent concurrent PrPSc fragments, and the 20 and
18.5 kDa fragments likely reflect specific PK cleavage sites,
the 20 and 18.5 kDa bands are distinguished from the type 1
and type 2 fragments because, at least to date, they were
never detected independently from types 1 and 2, and are
not markers of specific clinico-pathological phenotypes.
Knowledge of these regional variations is nonetheless
important to avoid misinterpreting a PrPSc profile as novel
when only one brain region is analyzed [21].
Finally, the results obtained from the analyses of lesion
profiles and clinical features in the subgroups of sCJD
cases with mixed features deserve further comment. By
showing that the relative ‘‘load’’ of each of the two PrPSc
types significantly correlates with disease duration, the
relative frequency of certain symptoms, and the ratio
between cortical and cerebellar pathology, our study pro-
vides further strong evidence for the PrPSc type being a
major biological determinant in human prion disease.
In conclusion, the present data add to our knowledge of
the prevalence and phenotypic spectrum of the sCJD
variants with mixed molecular and pathological features,
provide an updated molecular classification of the disease
subtypes and will serve for future epidemiologic and
transmission studies aimed at disclosing the etiology and
extent of strain variation in sCJD.
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